

Vincenzo Brescia Morra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3739870/publications.pdf>

Version: 2024-02-01

17
papers

475
citations

759233

12
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

972
citing authors

#	ARTICLE	IF	CITATIONS
1	Atorvastatin Combined To Interferon to Verify the Efficacy (ACTIVE) in relapsing/remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Multiple Sclerosis Journal, 2010, 16, 450-454.	3.0	79
2	Levetiracetam for cerebellar tremor in multiple sclerosis. Journal of Neurology, 2006, 253, 762-766.	3.6	56
3	A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results. Journal of Neurology, 2012, 259, 132-138.	3.6	47
4	Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study. American Journal of Neuroradiology, 2019, 40, 99-106.	2.4	39
5	A randomized clinical trial of lithium in multiple system atrophy. Journal of Neurology, 2013, 260, 458-461.	3.6	36
6	A randomized controlled pilot trial of lithium in spinocerebellar ataxia type 2. Journal of Neurology, 2015, 262, 149-153.	3.6	32
7	Uric acid in relapsing/remitting multiple sclerosis: a 2-year longitudinal study. Journal of Neurology, 2015, 262, 961-967.	3.6	29
8	How many injections did you miss last month? A simple question to predict interferon β -1a adherence in multiple sclerosis. Expert Opinion on Drug Delivery, 2015, 12, 1829-1835.	5.0	28
9	Neuropsychological assessment, quantitative MRI and ApoE gene polymorphisms in a series of MS patients treated with IFN beta-1b. Journal of the Neurological Sciences, 2006, 245, 141-145.	0.6	27
10	Clinical use of frataxin measurement in a patient with a novel deletion in the FXN gene. Journal of Neurology, 2013, 260, 1116-1121.	3.6	26
11	No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β 1b therapy in relapsing/remitting multiple sclerosis (the ARIANNA study). Multiple Sclerosis Journal, 2016, 22, 1163-1173.	3.0	24
12	Chronic cerebrospinal venous insufficiency in multiple sclerosis: a highly prevalent age-dependent phenomenon. BMC Neurology, 2013, 13, 20.	1.8	19
13	Screening for dopa-responsive dystonia in patients with scans without evidence of dopaminergic deficiency (SWEDD). Journal of Neurology, 2014, 261, 2204-2208.	3.6	12
14	Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment. Journal of Neurology, 2019, 266, 361-368.	3.6	9
15	Vitamin K cream reduces reactions at the injection site in patients with relapsing/remitting multiple sclerosis treated with subcutaneous interferon beta β "VIKING study. Multiple Sclerosis Journal, 2015, 21, 1215-1216.	3.0	6
16	Voxel-based analysis of gray matter relaxation rates shows different correlation patterns for cognitive impairment and physical disability in relapsing-remitting multiple sclerosis. NeuroImage: Clinical, 2020, 26, 102201.	2.7	4
17	A polynomial regression-based approach to estimate relaxation rate maps suitable for multiparametric segmentation of clinical brain MRI studies in multiple sclerosis. Computer Methods and Programs in Biomedicine, 2022, 223, 106957.	4.7	2